Paper39499641
VEGF inhibition increases expression of HIF-regulated angiogenic genes by the RPE limiting the response of wet AMD eyes to aflibercept.
Sharma D and 13 others. Proc Natl Acad Sci U S A, 2024. Cited by 17 papers, by iCite.
Cite this record
ConductScience Library. VEGF inhibition increases expression of HIF-regulated angiogenic genes by the RPE limiting the response of wet AMD eyes to aflibercept. Papers, record 39499641. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39499641
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- VEGF inhibition increases expression of HIF-regulated angiogenic genes by the RPE limiting the response of wet AMD eyes to aflibercept.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptors, Vascular Endothelial Growth Factor | Major topic |
| Angiopoietin-Like Protein 4 | Major topic |
| Retinal Pigment Epithelium | Major topic |
| Vascular Endothelial Growth Factor A | Major topic |
| Hypoxia-Inducible Factor 1, alpha Subunit | Major topic |
| Recombinant Fusion Proteins | Major topic |
| Choroidal Neovascularization | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Wet Macular Degeneration | |
| Angiogenesis Inhibitors | |
| Gene Expression Regulation | |
| Male | |
| Female |
Source PubMed
Grants10
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| Sybil B. Harrington Stein Innovation Award | Research to Prevent Blindness (RPB) | PubMed | PubMed | ||
| P30 EY001765 | NEI NIH HHS | United States | P30EY001765 | PubMed and NIH | NIH RePORTER |
| TEDCO Maryland Innovation Initiative | State of Maryland (The State of Maryland) | PubMed | PubMed | ||
| unrestricted grant | Research to Prevent Blindness (RPB) | PubMed | PubMed | ||
| R01 EY032104 | NEI NIH HHS | United States | R01EY032104 | PubMed and NIH | NIH RePORTER |
| Branna and Irving Sisenwein Professorship | Branna and Irving Sisenwein Professorship | PubMed | PubMed | ||
| R01 EY029750 | NEI NIH HHS | United States | R01EY029750 | PubMed and NIH | NIH RePORTER |
| Special Scholar Award | Research to Prevent Blindness (RPB) | PubMed | PubMed | ||
| EY001765 | HHS | NIH | National Eye Institute (NEI) | P30EY001765 | PubMed and NIH | NIH RePORTER | |
| C. Michael Armstrong Professorship | Armstrong Family Foundation | PubMed | PubMed |
References50
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 2587050 | Atrophic macular degeneration. Rate of spread of geographic atrophy and visual loss. | Ophthalmology | 1989 | https://conductscience.org/library/papers/2587050 | PubMed |
| 2 | 9486038 | Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes. | Br J Ophthalmol | 1997 | https://conductscience.org/library/papers/9486038 | PubMed |
| 3 | 9204896 | Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. | Science | 1997 | https://conductscience.org/library/papers/9204896 | PubMed |
| 4 | 27156698 | Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. | Ophthalmology | 2016 | https://conductscience.org/library/papers/27156698 | PubMed |
| 5 | 22523653 | Anti-VEGF Treatment Strategies for Wet AMD. | J Ophthalmol | 2012 | https://conductscience.org/library/papers/22523653 | PubMed |
| 6 | 19834034 | Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt. | Invest Ophthalmol Vis Sci | 2010 | https://conductscience.org/library/papers/19834034 | PubMed |
| 7 | 24727261 | Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). | Am J Ophthalmol | 2014 | https://conductscience.org/library/papers/24727261 | PubMed |
| 8 | 31545295 | Angiopoietin-like 4 binds neuropilins and cooperates with VEGF to induce diabetic macular edema. | J Clin Invest | 2019 | https://conductscience.org/library/papers/31545295 | PubMed |
| 9 | 26477842 | Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results. | Ophthalmology | 2016 | https://conductscience.org/library/papers/26477842 | PubMed |
| 10 | 26469243 | Angiopoietin-like 4 as an Emerging Therapeutic Target for Diabetic Eye Disease. | JAMA Ophthalmol | 2015 | https://conductscience.org/library/papers/26469243 | PubMed |
| 11 | 20065104 | Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. | FASEB J | 2010 | https://conductscience.org/library/papers/20065104 | PubMed |
| 12 | 37227777 | Targeting hypoxia-inducible factors with 32-134D safely and effectively treats diabetic eye disease in mice. | J Clin Invest | 2023 | https://conductscience.org/library/papers/37227777 | PubMed |
| 13 | 23701276 | Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases. | Curr Drug Targets | 2013 | https://conductscience.org/library/papers/23701276 | PubMed |
| 14 | 32045141 | Aflibercept and Ranibizumab Modulate Retinal Pigment Epithelial Cells Function by Acting on Their Cross Talk with Vascular Endothelial Cells. | Cell Physiol Biochem | 2020 | https://conductscience.org/library/papers/32045141 | PubMed |
| 15 | 30834517 | Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. | Cochrane Database Syst Rev | 2019 | https://conductscience.org/library/papers/30834517 | PubMed |
| 16 | 26039997 | Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy. | Proc Natl Acad Sci U S A | 2015 | https://conductscience.org/library/papers/26039997 | PubMed |
| 17 | 19805192 | Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. | Proc Natl Acad Sci U S A | 2009 | https://conductscience.org/library/papers/19805192 | PubMed |
| 18 | 24875610 | Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. | JAMA Ophthalmol | 2014 | https://conductscience.org/library/papers/24875610 | PubMed |
| 19 | 34874918 | Aqueous proteins help predict the response of patients with neovascular age-related macular degeneration to anti-VEGF therapy. | J Clin Invest | 2022 | https://conductscience.org/library/papers/34874918 | PubMed |
| 20 | 613523 | Senile macular degeneration: a histopathologic study. | Trans Am Ophthalmol Soc | 1977 | https://conductscience.org/library/papers/613523 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42752553 | Angiopoietin-Like 4 Induces Upregulation of VEGF and sVCAM1 Through JNK/c-Jun and JAK2/STAT5 Signaling Pathways. | Invest Ophthalmol Vis Sci | 2026 | https://conductscience.org/library/papers/42752553 | PubMed |
| 42326539 | An intraocular oxygenated emulsion suppresses retinal fibrosis by inhibiting hypoxia-driven bioenergetic shifts and mesenchymal transformation. | Res Sq | 2026 | https://conductscience.org/library/papers/42326539 | PubMed |
| 41978200 | Cocoa Powder Modulates HIF-1α Stability and Inhibits Ocular Angiogenic and Degenerative Pathology. | Nutrients | 2026 | https://conductscience.org/library/papers/41978200 | PubMed |
| 41898816 | Precision Is Not Enough: When Tools Outpace Translation in Ocular Gene Therapy. | Genes (Basel) | 2026 | https://conductscience.org/library/papers/41898816 | PubMed |
| 41805097 | Silencing of lncRNA HOTAIR Using Eyedrops as a Potential Treatment for Diabetes-Associated Retinal Dysregulation and Dysfunction. | Invest Ophthalmol Vis Sci | 2026 | https://conductscience.org/library/papers/41805097 | PubMed |
| 41766669 | Molecular stress and neurovascular injury in the diabetic retina. | J Clin Invest | 2026 | https://conductscience.org/library/papers/41766669 | PubMed |
| 41575610 | Enhancing the efficacy of VEGF inhibitors by co-inhibition of HIF in the treatment of glioblastoma. | Apoptosis | 2026 | https://conductscience.org/library/papers/41575610 | PubMed |
| 41082699 | Hesperidin and Hesperetin from Orange Peel Water Extract Protect against NaIO3-Induced Oxidative Damage in Retinal Pigment Epithelial Cells by Modulating PI3K/Akt/HIF-1α/BNIP3 Signaling. | J Agric Food Chem | 2025 | https://conductscience.org/library/papers/41082699 | PubMed |
| 40937643 | PM2.5 exposure induces transcriptomic changes in ARPE-19 cells with activation of TGFβ-mediated signaling pathways: A next-generation sequencing approach. | J Chin Med Assoc | 2025 | https://conductscience.org/library/papers/40937643 | PubMed |
| 40668060 | Inhibition of Endothelial HIF-1α by IDF-11774 Attenuates Retinal Neovascularization and Vascular Leakage. | Invest Ophthalmol Vis Sci | 2025 | https://conductscience.org/library/papers/40668060 | PubMed |
| 40493193 | Feedback regulation between histone lactylation and ALKBH3-mediated glycolysis regulates age-related macular degeneration pathology. | Proc Natl Acad Sci U S A | 2025 | https://conductscience.org/library/papers/40493193 | PubMed |
| 40448612 | SUMOylation is a Translatable Target in Hypoxic MNPs Regulating Retinal Vasculopathy. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40448612 | PubMed |
| 40265403 | Novel Therapeutic Approaches for Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration. | Vision (Basel) | 2025 | https://conductscience.org/library/papers/40265403 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ANGPTL4 | 51129 | PubTator's text mining | https://conductscience.org/library/genes/51129 | NCBI Gene |
| HIF1A | 3091 | PubTator's text mining | https://conductscience.org/library/genes/3091 | NCBI Gene |
| KDR | 3791 | PubTator's text mining | https://conductscience.org/library/genes/3791 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39499641
GET https://conductscience.org/api/papers/v1/39499641/references?page=2